Johns Hopkins ABX Guide
Oritavancin
INDICATIONS
FDA
FDA
- Acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organisms
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 19, 2022
Citation
Auwaerter, Paul G, and Kathryn Dzintars. "Oritavancin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2022. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540648/all/Oritavancin.
Auwaerter PG, Dzintars K. Oritavancin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540648/all/Oritavancin. Accessed June 7, 2023.
Auwaerter, P. G., & Dzintars, K. (2022). Oritavancin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540648/all/Oritavancin
Auwaerter PG, Dzintars K. Oritavancin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2022. [cited 2023 June 07]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540648/all/Oritavancin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Oritavancin
ID - 540648
A1 - Auwaerter,Paul,M.D.
AU - Dzintars,Kathryn,PharmD, BCPS
Y1 - 2022/10/19/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540648/all/Oritavancin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
